Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities

Vallath Sabari, Hynds Robert E., Succony Laura, Janes Sam M., Giangreco Adam

Source: Eur Respir J 2014; 44: 513-522

Journal Issue: August

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Vallath Sabari, Hynds Robert E., Succony Laura, Janes Sam M., Giangreco Adam. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J 2014; 44: 513-522

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease Source: Eur Respir J, 56 (2) 1902320; 10.1183/13993003.02320-2019 Year: 2020
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021 Year: 2021
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020
The promise of mTOR signaling as a therapeutic target for IPF Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference Year: 2020
Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022
Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD) Source: ERS Lung Science Conference 2017 Year: 2017
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019
Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015
Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010
Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004